Medicine from the anticoagulant group (prevents blood clotting), antithrombotic drugs, low molecular weight heparin, in the form of solution for injection.
Inhixa is indicated in adults for:
Prevention of venous thromboembolic disease in surgical patients with medium or high risk, especially in orthopaedic or general surgery, including cancer surgery.
Prevention of venous thromboembolic disease in internal patients with acute disease (such as acute heart failure, respiratory failure, severe infection or rheumatic disease) and reduced mobility and increased risk of venous thromboembolic accident.
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), other than PE that may require thromboembolic treatment or surgery.
Prevention of extracorporeal circulation thrombus formation during dialysis
Acute coronary syndrome:
Treatment of unstable angina and myocardial infarction without ST segment elevation (NSTEMI) in combination with oral acetylsalicylic acid
Treatment of ST segment elevation acute myocardial infarction (STEMI), including patients for whom conservative (pharmacological) treatment is planned or patients with subsequent interventional treatment - percutaneous coronary intervention (PCI).
low molecular weight heparin
Medication strengths and packagings
Inhixa 2 000 IU (20 mg) /0,2 ml pre-filled syringe
The obligation to establish a Publicly Accessible Professional Information Service (PAPIS)
result from Act No. 378/2007 Sb., O léčivech. Information on our products can be
found on the website of the State Institute for Drug Control (SÚKL) in the
Product information (SPC or PIL) is available by clicking on the product name and the
Summary of Product Characteristics (SPC) link.
The Publicly Accessible Professional Information Service (PAPIS) for Inhixa
is operated by the marketing authorization holder - Pharma-Service International s.r.o., contact: